Hubungan Kadar Procalcitonin dengan beratnya Pneumonia Komunitas
DAFTAR PUSTAKA
Aabenhus R. Jansen JUS. Procalcitonin-Guided antibiotic treatment of respiratory
tract infection in primary care setting : are we there yet?Prim care Respir
J.2011;20:305-19.
American College of Chest Physicians/Society of Critical Care Medicine Consensus
Conference : Definitions for Sepsis and Organ Failure and Guidelines for The
Use of Innovative Therapies in Sepsis. Critical Care Medicine, 1992. Vol 20
no 6.
Bont J, Hak E, Hoes AW, Macfarlane JT, Varheiji TJM. Predicitng Death in Elderly
Patients with Community Acquired Pneumonia : A Prospective Validation
Study Re-evaluating the CRB-65 Severity Assessment Tool. Arch Intern Med.
2008; 168:1465-68.
Capelastegui A, Espana PP, Quintana JM, Arcitio I, Gorondo I, Egurolla M, et.al.
Validation of Predictive Rule for the management of Community Acquired
Pneumonia. Eur Respir J. 2006; 27: 151-57.
Carol P. Kathryn JG. Alteration of Urinary System. In:Essentials of Pathophysiology.
Lippincott Williams and Wilkins, 2003:411.
Crain C. Procalcitonin. Department of Anaesthetics. University of Kwazulu-Natal.
2010: 3 – 24.
Chastre J, Luyt CE, Trouillet JL, Combes A. New Diagnostic and Prognostic Markers
of Ventilator Associated Pneumonia . Current Opnion in Critical Care. 2006;
12: 446-51.
Christ-Crain M, Stolz D, Bingisser R, Mueller C, Mledinger D, Huber P, et.al.
Procalcitonin Guidance of Antibiotics Therapy in Community Acquired
Pneumonia. Am J Respir Crit Care Med. 2006; 174: 84 -93.
Christ-Crain M, Opal SM. Clinical Review: The Role of Biomarkers in the Diagnosis
and Management of Community Acquired Pneumonia. Critical care. 2010; 14:
1- 11.
Dahlan Z. Pandangan Baru Pneumonia Atipik dan Terapinya. Cermin Dunia
Kedokteran. 2000;128: 6.
30
Universitas Sumatera Utara
Dahlan Z. Pneumonia. Dalam: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M,
Setiati S (editors). Buku Ajar Ilmu Penyakit Dalam: Interna Publishing;
2009:2196-2206
De Frances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital
Discharge Survey. National Health Statistic Reports. 2008;5: 1 – 20.
Dremsizov T, Clermont G, Kellum JA, Kallassian KG, Fine MJ, Angus DC. Severe
Sepsis in CAP : When Does It Happen, and do SIRS Help Predict
Course?Chest, 2006; 129:968-78.
Gilber DN. Use of Plasma Procalcitonin Levels as an Adjunct to Clinical
Microbiology. Journal of Clinical Microbiology. July 2010:2325-29.
Hendlund J, Hansson LO. Procalcitonin and C-Reactive Protein Levels in Community
Acquired Pneumonia: Correlation With Etiology and Prognosis. Infection.
2000; 28: 68 – 72.
Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et.al. Risk
Prediction with Procalcitonin and Clinical Rules in Community Acqiured
Pneumonia. Ann Emerg Med. 2008; 52(1): 48- 58.
Irwin AD, Carrol ED. Procalcitonin. Arch Dis Child Educ Parc Ed.2011:228-33.
Jung DY, Park JB, Lee EN, Lee HT, Joh JW, Kwon CH, et. al. Combined use of
Myeloid-related protein 8/14 and Procalcitonin as diagnostic markers for acute
allograft
rejection
in
kidney
transplantation
recipients.
Transplant
Immunology. 2008; 18: 338-43.
Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, et.al.
Pneumonia: Still the Oldman’s Friend?. Arch Intern Med. 2003; 163: 317-23.
Kosanke R, Beier W, Lipecky R, Meisner M. Clinical Benefits of Procalcitonin.
Tannafos. 2008; 7:14 – 18.
Kruger S, Ewig S, Marne R, Papassotisiou J, Richter K, Von Baum H, et.al.
Procalcitonin Predicts Patient at Low Risk of Death from Community
Acquired Pneumonia Across all CRB-65 Classes. Eur Respir J. 2008; 31: 34955.
Laterre PF, Garber G, Levy H, Wunderink R. Kinasewitz GT, Sollet JP, et al. Severe
Community Acquired Pneumonia as Cause of severe sepsis : data from
PROWESS study.Crit.Care Med, 2005;33(5):952-61.
31
Universitas Sumatera Utara
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et.al. British
Thoracic Society Guidelines For The Management of Community Acquired
Pneumonia in Adults: update 2009. Thorax. 2009; 64(suppl II): 1 – 55.
Maier M, Wutzler S, Lehnert M, Szermutzky, Hendrik W, Bingold T, et.al. Serum
Procalcitonin Level in Patients with Multiple Injuries Including Viseral
Trauma. Journals of Trauma. 2009; 66: 243-49.Summary Executive. Pola
Penyakit Penyebab Kematian di Indonesia. Survei Kesehatan Rumah Tangga
(SKRT). 2001: 2.
Mandell LA, Wunderik RG, Arzueto A, Bartlett JG, Campbell GD, Dean NC, et.al.
Infectious Diseases Society of America/ American Thoracic Society
Consensus Guidelines on The Management of Community Acquired
Pneumonia in Adults. CID. 2007; 44: 27- 72.
Masia M, Gutierrez F, Shum C, Padilla, Sergio, et.al. Usefulness of Procalcitonin
Level in Community Acquired Pneumonia According to Patients Outcome
Research Team Pneumonia Severity Index. Chest. 2005; 128: 23-29.
Michael J.Fine,Thomas E.Auble, Donald M. Yealy. A Prediction Rule to identify
Low-Risk patients With Community Acquired Pneumonia,NEJM 1997; 336,
243-250.
Mira JP, Max A, Burgel PR. The Role of Biomarker in Community Acquired
Pneumonia: Prediciting Mortality and Response to Adjunctive Therapy.
Critical Care. 2008;12(Suppl 6): 1-7.
Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et.al. Diagnostic and
Prognostic Accuracy of Clinical and Laboratory Parameters in Community
Acquired Pneumonia. BMC Infectious Diseases. 2007; 7: 1- 10.
Nayak SB, Sakhamuri MS, Raghunanan B, Allison A, Uppalapati K, Patcha K. The
role of serum markers in assessing the severity and outcome of community
acquired pneumonia in Trinidadion population. Journal of Public Health and
Epidemiology. 2010:20-24.
Querol-Ribelles JM, Tenias JM, Grav E, Querol-Borras JM, Climent JL, Gomez E,
et.al. Plasma d-dimer levels correlate with outcomes in patient with
Community Acquired Pneumonia. Chest. 2004; 126: 1087-92.
32
Universitas Sumatera Utara
Rosner MH, Okusa MD. Patogenesis and etiology of post ischemic acute tubular
necrosis. Update 2009. Available from http//www.uptodate.com
Rumende CM. Procalcitonin dan Lipopolysaccharide-Binding Protein sebagai
prediktor dan petanda prognostik ventilator associated pneumonia pada pasien
HCU/ICU RSCM tahun 2006-2007. Diunduh dari majalah : www.majalahfarmacia.com/rubrik/one.news.
Shuetz P. Albrich W, Muller B. Procalcitonin for diagnosis of infection and guide to
antibiotic decision : past, present and future. BMC 2011;9:107.
Shuetz P, Christ Crain M, Muller B. Procalcitonin and other biomarkers to improve
assessment and antibiotic stedwarship in infection-hope for hype?SWISS
MED WKLY 2009;139:318-26.
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum Procalcitonin and CRaective Protein Levels as Markers of Bacterial Infection : a systmatic review
and meta-analysis. Clin Infect Disease 2004;39:206-17.
Summah H, Qu JM. Biomarkers: A Definite Plus in Pneumonia. Mediator of
Inflamation. 2009: 1-9.
Tseng JS, Chan MC, Hsu JY, Kuo BIT, Wu CL. Procalcitonin is a Valuable
Prognostic Markers in ARDS caused by Community Acquired Pneumonia.
Respirology. 2008;13: 505-9.
33
Universitas Sumatera Utara
Aabenhus R. Jansen JUS. Procalcitonin-Guided antibiotic treatment of respiratory
tract infection in primary care setting : are we there yet?Prim care Respir
J.2011;20:305-19.
American College of Chest Physicians/Society of Critical Care Medicine Consensus
Conference : Definitions for Sepsis and Organ Failure and Guidelines for The
Use of Innovative Therapies in Sepsis. Critical Care Medicine, 1992. Vol 20
no 6.
Bont J, Hak E, Hoes AW, Macfarlane JT, Varheiji TJM. Predicitng Death in Elderly
Patients with Community Acquired Pneumonia : A Prospective Validation
Study Re-evaluating the CRB-65 Severity Assessment Tool. Arch Intern Med.
2008; 168:1465-68.
Capelastegui A, Espana PP, Quintana JM, Arcitio I, Gorondo I, Egurolla M, et.al.
Validation of Predictive Rule for the management of Community Acquired
Pneumonia. Eur Respir J. 2006; 27: 151-57.
Carol P. Kathryn JG. Alteration of Urinary System. In:Essentials of Pathophysiology.
Lippincott Williams and Wilkins, 2003:411.
Crain C. Procalcitonin. Department of Anaesthetics. University of Kwazulu-Natal.
2010: 3 – 24.
Chastre J, Luyt CE, Trouillet JL, Combes A. New Diagnostic and Prognostic Markers
of Ventilator Associated Pneumonia . Current Opnion in Critical Care. 2006;
12: 446-51.
Christ-Crain M, Stolz D, Bingisser R, Mueller C, Mledinger D, Huber P, et.al.
Procalcitonin Guidance of Antibiotics Therapy in Community Acquired
Pneumonia. Am J Respir Crit Care Med. 2006; 174: 84 -93.
Christ-Crain M, Opal SM. Clinical Review: The Role of Biomarkers in the Diagnosis
and Management of Community Acquired Pneumonia. Critical care. 2010; 14:
1- 11.
Dahlan Z. Pandangan Baru Pneumonia Atipik dan Terapinya. Cermin Dunia
Kedokteran. 2000;128: 6.
30
Universitas Sumatera Utara
Dahlan Z. Pneumonia. Dalam: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M,
Setiati S (editors). Buku Ajar Ilmu Penyakit Dalam: Interna Publishing;
2009:2196-2206
De Frances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital
Discharge Survey. National Health Statistic Reports. 2008;5: 1 – 20.
Dremsizov T, Clermont G, Kellum JA, Kallassian KG, Fine MJ, Angus DC. Severe
Sepsis in CAP : When Does It Happen, and do SIRS Help Predict
Course?Chest, 2006; 129:968-78.
Gilber DN. Use of Plasma Procalcitonin Levels as an Adjunct to Clinical
Microbiology. Journal of Clinical Microbiology. July 2010:2325-29.
Hendlund J, Hansson LO. Procalcitonin and C-Reactive Protein Levels in Community
Acquired Pneumonia: Correlation With Etiology and Prognosis. Infection.
2000; 28: 68 – 72.
Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et.al. Risk
Prediction with Procalcitonin and Clinical Rules in Community Acqiured
Pneumonia. Ann Emerg Med. 2008; 52(1): 48- 58.
Irwin AD, Carrol ED. Procalcitonin. Arch Dis Child Educ Parc Ed.2011:228-33.
Jung DY, Park JB, Lee EN, Lee HT, Joh JW, Kwon CH, et. al. Combined use of
Myeloid-related protein 8/14 and Procalcitonin as diagnostic markers for acute
allograft
rejection
in
kidney
transplantation
recipients.
Transplant
Immunology. 2008; 18: 338-43.
Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, et.al.
Pneumonia: Still the Oldman’s Friend?. Arch Intern Med. 2003; 163: 317-23.
Kosanke R, Beier W, Lipecky R, Meisner M. Clinical Benefits of Procalcitonin.
Tannafos. 2008; 7:14 – 18.
Kruger S, Ewig S, Marne R, Papassotisiou J, Richter K, Von Baum H, et.al.
Procalcitonin Predicts Patient at Low Risk of Death from Community
Acquired Pneumonia Across all CRB-65 Classes. Eur Respir J. 2008; 31: 34955.
Laterre PF, Garber G, Levy H, Wunderink R. Kinasewitz GT, Sollet JP, et al. Severe
Community Acquired Pneumonia as Cause of severe sepsis : data from
PROWESS study.Crit.Care Med, 2005;33(5):952-61.
31
Universitas Sumatera Utara
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et.al. British
Thoracic Society Guidelines For The Management of Community Acquired
Pneumonia in Adults: update 2009. Thorax. 2009; 64(suppl II): 1 – 55.
Maier M, Wutzler S, Lehnert M, Szermutzky, Hendrik W, Bingold T, et.al. Serum
Procalcitonin Level in Patients with Multiple Injuries Including Viseral
Trauma. Journals of Trauma. 2009; 66: 243-49.Summary Executive. Pola
Penyakit Penyebab Kematian di Indonesia. Survei Kesehatan Rumah Tangga
(SKRT). 2001: 2.
Mandell LA, Wunderik RG, Arzueto A, Bartlett JG, Campbell GD, Dean NC, et.al.
Infectious Diseases Society of America/ American Thoracic Society
Consensus Guidelines on The Management of Community Acquired
Pneumonia in Adults. CID. 2007; 44: 27- 72.
Masia M, Gutierrez F, Shum C, Padilla, Sergio, et.al. Usefulness of Procalcitonin
Level in Community Acquired Pneumonia According to Patients Outcome
Research Team Pneumonia Severity Index. Chest. 2005; 128: 23-29.
Michael J.Fine,Thomas E.Auble, Donald M. Yealy. A Prediction Rule to identify
Low-Risk patients With Community Acquired Pneumonia,NEJM 1997; 336,
243-250.
Mira JP, Max A, Burgel PR. The Role of Biomarker in Community Acquired
Pneumonia: Prediciting Mortality and Response to Adjunctive Therapy.
Critical Care. 2008;12(Suppl 6): 1-7.
Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et.al. Diagnostic and
Prognostic Accuracy of Clinical and Laboratory Parameters in Community
Acquired Pneumonia. BMC Infectious Diseases. 2007; 7: 1- 10.
Nayak SB, Sakhamuri MS, Raghunanan B, Allison A, Uppalapati K, Patcha K. The
role of serum markers in assessing the severity and outcome of community
acquired pneumonia in Trinidadion population. Journal of Public Health and
Epidemiology. 2010:20-24.
Querol-Ribelles JM, Tenias JM, Grav E, Querol-Borras JM, Climent JL, Gomez E,
et.al. Plasma d-dimer levels correlate with outcomes in patient with
Community Acquired Pneumonia. Chest. 2004; 126: 1087-92.
32
Universitas Sumatera Utara
Rosner MH, Okusa MD. Patogenesis and etiology of post ischemic acute tubular
necrosis. Update 2009. Available from http//www.uptodate.com
Rumende CM. Procalcitonin dan Lipopolysaccharide-Binding Protein sebagai
prediktor dan petanda prognostik ventilator associated pneumonia pada pasien
HCU/ICU RSCM tahun 2006-2007. Diunduh dari majalah : www.majalahfarmacia.com/rubrik/one.news.
Shuetz P. Albrich W, Muller B. Procalcitonin for diagnosis of infection and guide to
antibiotic decision : past, present and future. BMC 2011;9:107.
Shuetz P, Christ Crain M, Muller B. Procalcitonin and other biomarkers to improve
assessment and antibiotic stedwarship in infection-hope for hype?SWISS
MED WKLY 2009;139:318-26.
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum Procalcitonin and CRaective Protein Levels as Markers of Bacterial Infection : a systmatic review
and meta-analysis. Clin Infect Disease 2004;39:206-17.
Summah H, Qu JM. Biomarkers: A Definite Plus in Pneumonia. Mediator of
Inflamation. 2009: 1-9.
Tseng JS, Chan MC, Hsu JY, Kuo BIT, Wu CL. Procalcitonin is a Valuable
Prognostic Markers in ARDS caused by Community Acquired Pneumonia.
Respirology. 2008;13: 505-9.
33
Universitas Sumatera Utara